Form 4: Revance Therapeutics President Dustin Sjuts Reports Stock Vesting
SEC Form 4 Filing
Dustin Sjuts, President of Revance Therapeutics, reports the vesting of performance-based restricted stock units (PSUs) on February 29, 2024.
Summary
- Dustin Sjuts, President of Revance Therapeutics, filed a Form 4 on March 4, 2024, reporting changes in beneficial ownership of the company's stock.
- On February 29, 2024, 22,110 shares of common stock were acquired due to the vesting of performance-based restricted stock units (PSUs).
- These PSUs were granted on January 31, 2023, and vest over three years based on revenue goal achievement.
- The Issuer's Compensation Committee certified a portion of the PSUs eligible to vest based on revenue goal achievement from January 1, 2023, through December 31, 2023.
- Vesting is subject to the Reporting Person remaining in continuous service through the vesting date of March 15, 2024.
- Following the transaction, Sjuts beneficially owns 179,728 shares of Revance Therapeutics common stock.
Sentiment
Score: 7
Explanation: The document indicates achievement of revenue goals, which is a positive sign. The vesting of PSUs is a standard practice, and the continued employment of the President is also a positive indicator.
Positives
- The vesting of PSUs indicates that Revance Therapeutics achieved certain revenue goals, which is a positive sign for the company's performance.
- Dustin Sjuts' continued employment through the vesting date (March 15, 2024) suggests stability in the company's leadership.
Future Outlook
The vesting of PSUs is contingent on continued service through March 15, 2024, suggesting an expectation of continued employment for Dustin Sjuts.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The vesting of PSUs is a common compensation practice used to incentivize executives to achieve company goals.
Stakeholder Impact
- Shareholders may view the vesting of PSUs as a positive sign, indicating that the company is achieving its goals.
- Employees may be motivated by the fact that executives are incentivized to achieve company goals.
Key Dates
| Date | Description |
|---|---|
| January 31, 2023 | Date of grant for performance-based restricted stock units (PSUs). |
| January 1, 2023 December 31, 2023 | Period for measuring revenue goal achievement for PSU vesting. |
| February 29, 2024 | Transaction date for the vesting of PSUs. |
| March 4, 2024 | Date of Form 4 filing. |
| March 15, 2024 | Vesting date, contingent on continuous service. |
Keywords
Revance Therapeutics, Dustin Sjuts, Form 4, Beneficial Ownership, Stock Vesting, PSUs, Revenue Goals, Compensation Committee
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.